AB-FUBINACA - Revision history

Adm1n at 23:44, 14 February 2015

2015-02-14T23:44:24Z

Adm1n: /* See also */

2015-02-14T23:44:02Z

‎See also

Adm1n: Created page with "AB-FUBINACA is a drug that acts as a potent agonist for the cannabinoid receptors, with Ki values of 0.9nM at CB1 and 23.2nM at CB2. It was originally developed by..."

2015-02-14T23:42:12Z

Created page with "AB-FUBINACA is a drug that acts as a potent agonist for the cannabinoid receptors, with Ki values of 0.9nM at CB1 and 23.2nM at CB2. It was originally developed by..."

New page

AB-FUBINACA is a drug that acts as a potent agonist for the [[cannabinoid receptor]]s, with Ki values of 0.9nM at [[CB1]] and 23.2nM at[[ CB2]]. It was originally developed by Pfizer in 2009 as an analgesic medication, but was never pursued for human use. Subsequently in 2012, this compound was discovered as an ingredient in [[synthetic cannabis]] blends in Japan, along with a related compound AB-PINACA which had not previously been reported.

In January 2014, AB-FUBINACA was designated as a Schedule I controlled substance in the United States.

==See also==

* [[AB-CHMINACA]]

* [[AB-PINACA]]

* [[ADB-FUBINACA]]

* [[ADBICA]]

* [[APICA]]

* [[APINACA]]

* [[Benzydamine]]

* [[NESS-040C5]]

* [[PF-03550096]]

← Older revision		Revision as of 23:44, 14 February 2015
Line 1:		Line 1:
−	AB-FUBINACA is a drug that acts as a potent agonist for the [[cannabinoid ~~receptor~~]]s, with Ki values of 0.9nM at [[CB1]] and 23.2nM at[[ CB2]]. It was originally developed by Pfizer in 2009 as an analgesic medication, but was never pursued for human use. Subsequently in 2012, this compound was discovered as an ingredient in [[synthetic cannabis]] blends in Japan, along with a related compound AB-PINACA which had not previously been reported.	+	AB-FUBINACA is a drug that acts as a potent agonist for the [[cannabinoid receptors]], with Ki values of 0.9nM at [[CB1]] and 23.2nM at[[ CB2]]. It was originally developed by Pfizer in 2009 as an analgesic medication, but was never pursued for human use. Subsequently in 2012, this compound was discovered as an ingredient in [[synthetic cannabis]] blends in Japan, along with a related compound AB-PINACA which had not previously been reported.

	In January 2014, AB-FUBINACA was designated as a Schedule I controlled substance in the United States.		In January 2014, AB-FUBINACA was designated as a Schedule I controlled substance in the United States.

@@ Line 17: / Line 17: @@
 * [[APINACA]]
 * [[NESS-040C5]]
 * [[PF-03550096]]